New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 10, 2014
11:42 EDTGILD, RHHBY, GSKReport claims Tamiflu, Relenza do little to prevent the spread of flu
The Cochrane Collaboration, an independent nonprofit organization that aims to help health professionals, patients, and policy makers access evidence-based medicine to guide their decisions, concluded in a newly published report that neuraminidase inhibitors Tamiflu and Relenza are stockpiled and recommended by public health agencies but have not been proven to prevent the spread of flu or reduce dangerous complications. Tamiflu was co-developed by and is marketed by Gilead Sciences (GILD) and Roche (RHHBY), while Relenza is marketed by GlaxoSmithKline (GSK). Roche said "we disagree with the overall conclusions" and warned they could "potentially have serious public health implications," according to a company statement quoted by BBC News. Reference Link
News For GILD;RHHBY;GSK From The Last 14 Days
Check below for free stories on GILD;RHHBY;GSK the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
July 23, 2014
07:09 EDTGSKGlaxoSmithKline reports Q2 core EPS down 12% to 19.1p
Subscribe for More Information
07:09 EDTGSKMylan wins restraining order against Apotex for generic version of GSK's Paxil
Subscribe for More Information
July 22, 2014
09:55 EDTGSKLupin, private equity funds weigh bids for GSK's older drugs, Reuters reports
Subscribe for More Information
06:14 EDTGILDGilead July weekly volatility elevated into Q2
Subscribe for More Information
05:21 EDTRHHBYRoche announces Genentech Avastin granted priority review by FDA
Subscribe for More Information
July 21, 2014
16:00 EDTGILDOptions Update; July 21, 2014
iPath S&P 500 VIX Short-Term Futures up 65c to 28.53. Option volume leaders: AAPL FB NFLX DG CMCSA GILD PBR TWTR TSLA according to Track Data.
09:38 EDTGILDActive equity options trading on open
Subscribe for More Information
07:21 EDTGILDGilead could be hurt by new HCV drugs, says Wells Fargo
Noting that data on a new Merck (MRK) HCV treatment is expected in November, Wells Fargo thinks Merck's HCV drug could be combined with Gilead's (GILD) Sovaldi to shorten the duration of treatment to four weeks. Other companies could take similar actions, and Gilead's per patient revenues would be significantly reduced if this occurs, the firm warned. However, it continues to have an upbeat outlook on Gilead heading into what it sees as a strong quarter and is still upbeat on the company's long-term HCV opportunity. It keeps an Outperform rating on Gilead.
07:11 EDTGSK, RHHBYInternational Society of DNA Vaccines to hold a conference
Subscribe for More Information
06:43 EDTRHHBY, GILDGrowing market for hepatitis-C treatment prompts legal scramble, WSJ says
Subscribe for More Information
July 20, 2014
15:42 EDTRHHBYRoche not looking for big acquisitions, Reuters says
Subscribe for More Information
12:46 EDTGILDGilead drug cocktail helps treat HIV/HCV-coinfected patients, JAMA says
Subscribe for More Information
July 17, 2014
17:42 EDTRHHBYCepheid says Roche patent suit will not have material adverse impact on results
Subscribe for More Information
07:18 EDTGSKMylan wins motion to enjoin GlaxoSmithKline from production of generic product
Subscribe for More Information
06:23 EDTGSKGlaxoSmithKline admits to bribing Chinese officials in 2001, FT reports
Subscribe for More Information
July 16, 2014
11:57 EDTGILDStocks with call strike movement; GILD YHOO
Subscribe for More Information
11:23 EDTRHHBYRoche Alzheimer drug shows mixed results in trial, NYT says
Subscribe for More Information
07:14 EDTGSKIsis Pharmaceuticals earns $1M milestone payment from GlaxoSmithKline
Isis Pharmaceuticals (ISIS) has earned a $1M milestone payment from GlaxoSmithKline (GSK) related to the advancement of the Phase 2/3 study of ISIS-TTRRx in patients with familial amyloid polyneuropathy. ISIS-TTRRx is an antisense drug in development with GSK for the treatment of transthyretin amyloidosis, a severe and rare genetic disease characterized by progressive dysfunction of peripheral nerve and/or heart tissues. Including this milestone payment, Isis has generated $27M in upfront and milestone payments for advancing ISIS-TTRRx. If GSK elects to exercise its option to exclusively license the ISIS-TTRRx program, Isis is eligible to receive a license fee, regulatory and sales milestone payments and double-digit royalties on sales of ISIS-TTRRx.
06:26 EDTRHHBYBristol-Myers lung cancer trials being underestimated, says Citigroup
After building a statistical model of Bristol-Myers' two critical registration trials for Opdivo in lung cancer, Citigroup believes the market is "materially" underestimating both Phase III trials. Citi says potential Opdivo FDA approval in 2015 in lung cancer would give Bristol-Myers an up to two year lead time versus Merck (MRK) and Roche (RHHBY). The firm estimates 2023 Opdivo revenue at $7B and reiterates a Buy rating on Bristol with a $60 price target.
05:38 EDTGSKGSK, Theravance initiate Phase III IMPACT study
GlaxoSmithKline (GSK) and Theravance (THRX) announced the start of a global phase III study, known as IMPACT, to evaluate the efficacy and safety of the 'closed' triple combination of FF/UMEC/VI in patients with chronic obstructive pulmonary disease, or COPD. IMPACT is the first pivotal phase III study in a programme to evaluate a once-daily closed triple combination treatment of an inhaled corticosteroid, or ICS; a long-acting muscarinic antagonist, or LAMA; and a long-acting beta2-adrenergic agonist, or LABA, in patients with COPD. The IMPACT study will enrol approximately 10,000 patients and assess whether the combination of FF, or fluticasone furoate, an ICS, UMEC, or umeclidinium, a LAMA, and VI, or vilanterol, a LABA, all delivered in GSK's Ellipta inhaler, can reduce the annual rate of moderate and severe exacerbations compared with two approved once daily COPD treatments, Relvar/Breo Ellipta, FF/VI, which is an ICS/LABA combination, and Anoro Ellipta, UMEC/VI, which is a LAMA/LABA combination.
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use